OAM
RXRX icon

Oxford Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Oxford Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189K Sell
51,413
-20,340
-28% -$67.7K 0.09% 319
2026
Q1 		$220K Buy
71,753
+42,244
+143% +$163K 0.09% 339
2025
Q4 		$121K Buy
+29,509
New +$146K 0.04% 440

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Oxford Asset Management's RXRX Position: Q2 2026 in Review

Oxford Asset Management reduced its Recursion Pharmaceuticals (RXRX) stake by 28% in Q2 2026, selling an estimated $67.7K and leaving 51,413 shares worth $189K. The position accounts for 0.09% of the portfolio, ranked #319.

Oxford Asset Management first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $220K in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Oxford Asset Management held 51,413 shares of Recursion Pharmaceuticals worth $189K as of Q2 2026.
  • Oxford Asset Management sold 20,340 Recursion Pharmaceuticals shares in Q2 2026, an estimated $67.7K.
  • Recursion Pharmaceuticals made up 0.09% of Oxford Asset Management's portfolio in Q2 2026, its #319 holding.
  • Oxford Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Oxford Asset Management's Recursion Pharmaceuticals position peaked at $220K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.